An observational cohort study utilizes a national healthcare database to evaluate the efficacy of a newly approved intravenous antifungal agent compared to standard amphotericin B for the treatment of invasive mucormycosis. The primary outcome is 30-day all-cause mortality.
The initial analysis yields a crude relative risk () of (), suggesting that the new agent is associated with a significantly higher mortality risk compared to standard therapy.
Concerned about these findings, the investigators perform a stratified analysis based on the presence or absence of cavernous sinus thrombosis at the time of diagnosis. The results are shown below:
| Stratum | Relative Risk () |
|---|---|
| Cavernous sinus thrombosis present | () |
| Cavernous sinus thrombosis absent | () |
Based on these results, which of the following epidemiologic phenomena best explains the observed discrepancy between the crude and stratified relative risks?
- Preferential administration of the new agent to patients with more advanced disease at baselineCevap
- BDifferential magnitude of the new agent's efficacy depending on the presence of cavernous sinus thrombosis
- CCavernous sinus thrombosis acting as an intermediate step on the causal pathway between treatment and mortality
- DSelection of study participants based primarily on their mortality outcome rather than their exposure status
- EDisproportionate loss to follow-up among patients who received standard therapy and had severe disease